J&J Beats Q1 Earnings Expectations, Announces Dividend Increase After Hiking Prices on Dozens of Brand Name Drugs

This week, Johnson & Johnson kicked off the first round of Big Pharma earnings reports for the first quarter of 2022. Yet again, the Big Pharma giant surpassed Wall Street analysts’ earnings expectations, growing sales and posting massive profits after hiking prices on several prescription drugs in their portfolio amid the winter pandemic surge.

The blockbuster earnings come as Johnson & Johnson hiked prices on dozens of prescription drugs this year, adding to the growing list of price hikes the company has launched since the start of the COVID-19 pandemic.

Stay tuned as we continue to monitor earnings calls from Big Pharma for Q1 of 2022 over the next few weeks.

Learn more about solutions to lower prescription drug prices and hold Big Pharma accountable HERE.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.